Ayesha Ali

Ayesha Ali

Auto-generated profile, based on publicly available information

Ayesha Ali

Department of Radiation Oncology, Thomas Jefferson University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
AAAyesha S. Ali
Ayesha S. Ali
GMGregor Manukian
Gregor Manukian
JJJennifer M. Johnson
Jennifer M. Johnson
IVIoannis Vathiotis
Ioannis Vathiotis
RARita Axelrod
Rita Axelrod
VBVoichita Bar-Ad
Voichita Bar-Ad

18 October 2022 in Research Square
Verified
Preprint
Open access
PDF file
AAAyesha S Ali
Ayesha S Ali
ASAlexandria Smith
Alexandria Smith
ASAyako Shimada
Ayako Shimada
BSBrittany C Smith
Brittany C Smith
KHKamryn Hines
Kamryn Hines
NSNicole L Simone
Nicole L Simone
Background: Although the U.S. cancer death rate has declined significantly over three decades, health disparities continue to exist. Factors such as the environment in which our patients work, live, and play, also known as social determinants of health (SDoH), may play a role. Adverse SDoH are associated with increased cancer risk factors and negative health outcomes. Determining how SDoH may be linked to cancer beliefs could inform future interventions to decrease health disparities. Methods: Data from a population-level survey of an NCI-designated cancer center’s catchment area was used to calculate adverse SDoH scores ranging from 0 to 9 for 859 survey respondents. Spearman's correlation coefficients quantified the relationship between the SDoH score and six cancer belief items. Results: The majority of participants were less than 41 years old (60.4%), female (68.1%), and white (67%). The median SDoH score was 2, indicating the number of adverse SDoHs. Those with higher SDoH scores were more likely to agree that they would not like to know their cancer risk (p<0.001), that cancer is a death sentence (p<0.001) and there isn’t much you can do to lower your cancer risk (p<0.001). Conclusion: Adverse SDoHs may play a role in cancer beliefs and may influence patients’ willingness to engage in risk prevention behaviors or in their clinical care if diagnosed with cancer. Educational efforts to alter cancer beliefs can target those with increased adverse SDOH. Screening for and intervening on SDoH may increase cancer screening rates and clinical trial participation.

1 January 2022
Verified
Conference Paper
Open access
PDF file
WSWenyin Shi
Wenyin Shi
Ryan S MillerRyan S Miller
Ryan S Miller
ASAndrew Song
Andrew Song
AAAyesha Ali
Ayesha Ali
VBVoichita Bar-Ad
Voichita Bar-Ad
HLHaisong Liu
Haisong Liu
Shi W, et al. Brain Tumor Res Treat. 2022 Mar;10(Suppl):S86. https://doi.org/10.14791/btrt.2022.10.F-1378

1 January 2022
Verified
Conference Paper
Open access
PDF file
WSWenyin Shi
Wenyin Shi
AAAyesha Ali
Ayesha Ali
MNMuneeb Niazi
Muneeb Niazi
VBVoichita Bar-Ad
Voichita Bar-Ad
MWMaria Werner-Wasik
Maria Werner-Wasik
KJKevin Judy
Kevin Judy
Shi W, et al. Brain Tumor Res Treat. 2022 Mar;10(Suppl):S179. https://doi.org/10.14791/btrt.2022.10.F-1386

1 January 2022
Verified
Conference Paper
Open access
PDF file
WSWenyin Shi
Wenyin Shi
JTJames Taylor
James Taylor
Ryan S MillerRyan S Miller
Ryan S Miller
AAAyesha Ali
Ayesha Ali
VBVoichita Bad-Ad
Voichita Bad-Ad
KJKevin Judy
Kevin Judy
Shi W, et al. Brain Tumor Res Treat. 2022 Mar;10(Suppl):S180. https://doi.org/10.14791/btrt.2022.10.F-1389

10 February 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NWNoelle L. Williams
Noelle L. Williams
AAAyesha Ali
Ayesha Ali
TDTu Dan
Tu Dan
KZKyle Ziemer
Kyle Ziemer
BLBenjamin Leiby
Benjamin Leiby
ADAdam Paul Dicker
Adam Paul Dicker
216 Background: The importance of patient-reported outcomes (PROs) has been recognized and this data is increasingly being incorporated into modern radiotherapy (RT) trial design. Despite this, there is a lack of published data regarding collection and reporting of PRO data in the RT setting. We sought to systematically evaluate RT protocols to assess trends of PRO data collection and factors associated with reporting. Methods: We queried multi-institutional RT trials indexed on ClinicalTrials.gov, the Cochrane database, and MEDLINE and identified trials with full protocols available. We collected information in regards to study population, primary and secondary endpoints, quality of life measures, and PRO data. Descriptive and chi-squared analyses were employed to investigate trends and factors associated with PRO reporting. Results: 232 protocols were evaluable (1971-2014) from multiple cooperative groups. Of these, 198 were completed and 34 were in progress. Overall, only 41% of trials had protocol-specified collection of PROs. Of the 155 trials that had at least 1 published report, only 34 (22%) reported PRO data. All nine trials with PRO as a primary endpoint (9/9) had published reports with this information. Treatment era was associated with PRO collection, with 30% of trials collecting PRO data prior to 2005, 48% between 2006 and 2010, and 66% between 2011 and 2015 (X2 [4, N = 232] = 15.79, p = 0.003). PROs were most likely to be collected in phase III trials (X2 [4, N = 226] = 59.6, p < 0.0001). Conclusions: PROs are historically under collected and reported in cooperative group RT trials. Despite increasing PRO collection in modern trials, reporting remains suboptimal and may inaccurately inform survivorship issues. As digital literacy progresses, electronic PRO data may offer a potential avenue for improvement. Ultimately, PRO data will serve as a vital component to help define value in newly proposed payment models focused on improving quality of care while reducing cost of care.